Vaxart Inc
Cerrado
0.34
Resumen
Variación precio
24h
Mínimo
0.34
Máximo
0.34
Ingresos | -50M 5.2M |
|---|---|
Ventas | -65M 39M |
P/B Media del Sector | 3.938 49.888 |
BPA | 0.02 |
Margen de beneficios | 13.203 |
Empleados | 65 |
EBITDA | -51M 6.8M |
Próximas Ganancias | 12 ago 2026 |
|---|
Capitalización Mercado | -32M 152M |
|---|---|
Apertura anterior | 0.34 |
Cierre anterior | 0.34 |
Vaxart Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Vaxart Inc previsión
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.